New targeted therapies for treatment of thrombosis in antiphospholipid syndrome

Silvia S. Pierangeli, Mariano E. Vega-Ostertag, Emilio Gonzalez

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Antiphospholipid (aPL) antibodies (Abs) are associated with thrombosis and pregnancy loss in antiphospholipid syndrome (APS), a disorder initially characterised in patients with systemic lupus erythematosus (SLE) but now known to occur in the absence of other autoimmune disease. There is strong evidence that aPL Abs are pathogenic in vivo, from studies of animal models of thrombosis, endothelial cell activation and pregnancy loss. In recent years, progress has been made in characterising the molecular basis of this pathogenicity, which includes direct effects on platelets, endothelial cells and monocytes as well as activation of complement. This review summarises the clinical manifestations of APS and current modalities of treatment, and explains recent advances in understanding the molecular events triggered by aPL Abs on target cells in coagulation pathways as well as effects of aPL Abs on complement activation. Based on this information and on additional scientific evidence using in vitro and in vivo models, new potential targeted therapies for treatment and/or prevention of thrombosis in APS are proposed and discussed.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalExpert Reviews in Molecular Medicine
Volume9
Issue number30
DOIs
StatePublished - Nov 2007

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Thrombosis
Complement Activation
Chemical activation
Endothelial cells
Endothelial Cells
Pregnancy
Therapeutics
Platelets
Coagulation
Systemic Lupus Erythematosus
Autoimmune Diseases
Virulence
Monocytes
Animals
Blood Platelets
Animal Models

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Molecular Medicine

Cite this

New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. / Pierangeli, Silvia S.; Vega-Ostertag, Mariano E.; Gonzalez, Emilio.

In: Expert Reviews in Molecular Medicine, Vol. 9, No. 30, 11.2007, p. 1-15.

Research output: Contribution to journalArticle

Pierangeli, Silvia S. ; Vega-Ostertag, Mariano E. ; Gonzalez, Emilio. / New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. In: Expert Reviews in Molecular Medicine. 2007 ; Vol. 9, No. 30. pp. 1-15.
@article{70c200e749fd499ea2342e75bb9894a5,
title = "New targeted therapies for treatment of thrombosis in antiphospholipid syndrome",
abstract = "Antiphospholipid (aPL) antibodies (Abs) are associated with thrombosis and pregnancy loss in antiphospholipid syndrome (APS), a disorder initially characterised in patients with systemic lupus erythematosus (SLE) but now known to occur in the absence of other autoimmune disease. There is strong evidence that aPL Abs are pathogenic in vivo, from studies of animal models of thrombosis, endothelial cell activation and pregnancy loss. In recent years, progress has been made in characterising the molecular basis of this pathogenicity, which includes direct effects on platelets, endothelial cells and monocytes as well as activation of complement. This review summarises the clinical manifestations of APS and current modalities of treatment, and explains recent advances in understanding the molecular events triggered by aPL Abs on target cells in coagulation pathways as well as effects of aPL Abs on complement activation. Based on this information and on additional scientific evidence using in vitro and in vivo models, new potential targeted therapies for treatment and/or prevention of thrombosis in APS are proposed and discussed.",
author = "Pierangeli, {Silvia S.} and Vega-Ostertag, {Mariano E.} and Emilio Gonzalez",
year = "2007",
month = "11",
doi = "10.1017/S1462399407000506",
language = "English (US)",
volume = "9",
pages = "1--15",
journal = "Expert Reviews in Molecular Medicine",
issn = "1462-3994",
publisher = "Cambridge University Press",
number = "30",

}

TY - JOUR

T1 - New targeted therapies for treatment of thrombosis in antiphospholipid syndrome

AU - Pierangeli, Silvia S.

AU - Vega-Ostertag, Mariano E.

AU - Gonzalez, Emilio

PY - 2007/11

Y1 - 2007/11

N2 - Antiphospholipid (aPL) antibodies (Abs) are associated with thrombosis and pregnancy loss in antiphospholipid syndrome (APS), a disorder initially characterised in patients with systemic lupus erythematosus (SLE) but now known to occur in the absence of other autoimmune disease. There is strong evidence that aPL Abs are pathogenic in vivo, from studies of animal models of thrombosis, endothelial cell activation and pregnancy loss. In recent years, progress has been made in characterising the molecular basis of this pathogenicity, which includes direct effects on platelets, endothelial cells and monocytes as well as activation of complement. This review summarises the clinical manifestations of APS and current modalities of treatment, and explains recent advances in understanding the molecular events triggered by aPL Abs on target cells in coagulation pathways as well as effects of aPL Abs on complement activation. Based on this information and on additional scientific evidence using in vitro and in vivo models, new potential targeted therapies for treatment and/or prevention of thrombosis in APS are proposed and discussed.

AB - Antiphospholipid (aPL) antibodies (Abs) are associated with thrombosis and pregnancy loss in antiphospholipid syndrome (APS), a disorder initially characterised in patients with systemic lupus erythematosus (SLE) but now known to occur in the absence of other autoimmune disease. There is strong evidence that aPL Abs are pathogenic in vivo, from studies of animal models of thrombosis, endothelial cell activation and pregnancy loss. In recent years, progress has been made in characterising the molecular basis of this pathogenicity, which includes direct effects on platelets, endothelial cells and monocytes as well as activation of complement. This review summarises the clinical manifestations of APS and current modalities of treatment, and explains recent advances in understanding the molecular events triggered by aPL Abs on target cells in coagulation pathways as well as effects of aPL Abs on complement activation. Based on this information and on additional scientific evidence using in vitro and in vivo models, new potential targeted therapies for treatment and/or prevention of thrombosis in APS are proposed and discussed.

UR - http://www.scopus.com/inward/record.url?scp=36348973956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348973956&partnerID=8YFLogxK

U2 - 10.1017/S1462399407000506

DO - 10.1017/S1462399407000506

M3 - Article

VL - 9

SP - 1

EP - 15

JO - Expert Reviews in Molecular Medicine

JF - Expert Reviews in Molecular Medicine

SN - 1462-3994

IS - 30

ER -